Publications
Detailed Information
Adverse symptoms during short-term use of ulipristal acetate in women with uterine myomas and/or adenomyosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Yeon Hee | - |
dc.contributor.author | Han, Soo Jin | - |
dc.contributor.author | Lee, Dayong | - |
dc.contributor.author | Kim, Seul Ki | - |
dc.contributor.author | Jee, Byung Chul | - |
dc.creator | 지병철 | - |
dc.date.accessioned | 2020-01-23T07:42:02Z | - |
dc.date.available | 2020-04-05T07:42:02Z | - |
dc.date.created | 2020-01-30 | - |
dc.date.issued | 2019-04 | - |
dc.identifier.citation | Journal of Obstetrics and Gynaecology Research, Vol.45 No.4, pp.865-870 | - |
dc.identifier.issn | 1341-8076 | - |
dc.identifier.uri | https://hdl.handle.net/10371/163936 | - |
dc.description.abstract | Aim To evaluate various adverse symptoms during short-term use of ulipristal acetate in women with uterine myomas (n = 90), adenomyosis (n = 3) or both (n = 7). Methods One hundred premenopausal women who received ulipristal acetate for 4-12 weeks during 2016 to 2017 were selected. The medical records were reviewed and the following information was collected; adverse symptoms during medication, presence of menorrhagia or menstrual cramps, blood hemoglobin and liver function test. Adverse symptoms were recorded in the medical records as a checklist form including 76 specific progestin-related symptoms. Results Overall, the most frequent adverse symptom was amenorrhea (43%), followed by weight gain (29%), fatigue (27%), abdominal discomfort (21%), decreased menstrual flow (19%) and dizziness (18%). In 89 symptomatic women (with heavy menstrual bleeding and/or menstrual cramping pain and/or anemia), the most frequent adverse symptom was weight gain (27%) and fatigue (27%), followed by abdominal discomfort (21%), dry eye (18%), facial flushing (17%), dizziness (17%), headache (17%) and increased vaginal discharge (15%). Fourteen women stopped the medication due to unwanted adverse symptoms. Of this discontinuation group, major complaint was fatigue (50%), followed by weight gain (36%) and breast discomfort (35.7%). Conclusion Adverse symptoms were common and discontinuation rate was somewhat higher during short-term course of ulipristal acetate. Information about incidence of various adverse symptoms should be given to women who willing to take ulipristal acetate. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | en |
dc.publisher | Blackwell Publishing Inc. | - |
dc.title | Adverse symptoms during short-term use of ulipristal acetate in women with uterine myomas and/or adenomyosis | - |
dc.type | Article | - |
dc.identifier.doi | 10.1111/jog.13917 | - |
dc.citation.journaltitle | Journal of Obstetrics and Gynaecology Research | - |
dc.identifier.wosid | 000462919100013 | - |
dc.identifier.scopusid | 2-s2.0-85060618210 | - |
dc.description.srnd | OAIID:RECH_ACHV_DSTSH_NO:T201916404 | - |
dc.description.srnd | RECH_ACHV_FG:RR00200001 | - |
dc.description.srnd | ADJUST_YN: | - |
dc.description.srnd | EMP_ID:A079520 | - |
dc.description.srnd | CITE_RATE:1.122 | - |
dc.description.srnd | DEPT_NM:의학과 | - |
dc.description.srnd | EMAIL:blasto@snubh.org | - |
dc.description.srnd | SCOPUS_YN:Y | - |
dc.citation.endpage | 870 | - |
dc.citation.number | 4 | - |
dc.citation.startpage | 865 | - |
dc.citation.volume | 45 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Jee, Byung Chul | - |
dc.identifier.srnd | T201916404 | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordAuthor | adenomyosis | - |
dc.subject.keywordAuthor | adverse symptom | - |
dc.subject.keywordAuthor | discontinuation | - |
dc.subject.keywordAuthor | myoma | - |
dc.subject.keywordAuthor | ulipristal acetate | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.